Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)

What Was Tested

This clinical study looks at Semaglutide.

This will be the first study to compare the effects of switching from a DPP-4 inhibitor to oral semaglutide on glycaemic control in patients with T2D.

Why It Was Studied

Incretin-based therapies exert antihyperglycaemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent fashion.

The results will be disseminated in peer-reviewed journals and at scientific conferences.

Who Took Part

According to the abstract, 172 participants were involved.

Biochemical analyses and physical assessment will be performed, and adverse events will be recorded at baseline and at the end of the study.

How the Study Was Run

In design terms this was a randomized, open-label, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

Running at several centres spread the Semaglutide study over different clinics and patient groups.

The Semaglutide group and the comparison group ran side by side rather than switching.

This study is a multicentre, prospective, randomised, open-label, parallel-group trial.

The primary endpoint will be the effect of oral semaglutide on the change in HbA1c.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Glucagon-Like Peptides, Glycated Hemoglobin and Hypoglycemic Agents.

The authors tagged it with the keywords dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist and type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Semaglutide in 172 participants.

The publication is from 2022 (BMJ open), a journal based in England.

More context: the Semaglutide compound page, all human trials.